General MedicationsORALGeneric

TAVIST

CLEMASTINE FUMARATE

Standard Dose

EQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview TAVIST is listed in Drugs@FDA under application 018675 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CLEMASTINE FUMARATE Form and strength SYRUP;ORAL - EQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2002-02-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview TAVIST is listed in Drugs@FDA under application 018675 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CLEMASTINE FUMARATE Form and strength SYRUP;ORAL - EQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2002-02-11 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.